scholarly journals An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma

Sensors ◽  
2021 ◽  
Vol 21 (10) ◽  
pp. 3567
Author(s):  
Beata Szymanska ◽  
Zenon Lukaszewski ◽  
Beata Zelazowska-Rutkowska ◽  
Kinga Hermanowicz-Szamatowicz ◽  
Ewa Gorodkiewicz
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Tumor Resection ◽  
Analytical Signal ◽  
Cancer Marker ◽  
Human Epididymis Protein 4 ◽  
Pearson Coefficient ◽  
Rabbit Polyclonal Antibody ◽  
Good Agreement

Human epididymis protein 4 (HE4) is an ovarian cancer marker. Various cut-off values of the marker in blood are recommended, depending on the method used for its determination. An alternative biosensor for HE4 determination in blood plasma has been developed. It consists of rabbit polyclonal antibody against HE4, covalently attached to a gold chip via cysteamine linker. The biosensor is used with the non-fluidic array SPRi technique. The linear range of the analytical signal response was found to be 2–120 pM, and the biosensor can be used for the determination of the HE4 marker in the plasma of both healthy subjects and ovarian cancer patients after suitable dilution with a PBS buffer. Precision (6–10%) and recovery (101.8–103.5%) were found to be acceptable, and the LOD was equal to 2 pM. The biosensor was validated by the parallel determination of a series of plasma samples from ovarian cancer patients using the Elecsys HE4 test and the developed biosensor, with a good agreement of the results (a Pearson coefficient of 0.989). An example of the diagnostic application of the developed biosensor is given—the influence of ovarian tumor resection on the level of HE4 in blood serum.

Determination of Both TP53 Mutation Status and the Amount of p53 Protein Has Limited Diagnostic Importance for Patients with Ovarian Cancer

2022 ◽  
Vol 29 ◽  
Author(s):  
Sebastian M. Klein ◽  
Maria Bozko ◽  
Astrid Toennießen ◽  
Nisar P. Malek ◽  
Przemyslaw Bozko
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Tp53 Mutation ◽  
P53 Protein ◽  
Mutation Status ◽  
Tumor Tissues ◽  
Tp53 Status ◽  
Diagnostic Importance

Background: Ovarian cancer is one of the most aggressive types of gynecologic cancers. Many patients have a relapse within two years after diagnosis and subsequent therapy. Among different genetic changes generally believed to be important for the development of cancer, TP53 is the most common mutation in the case of ovarian tumors. Objective: Our work aims to compare the outcomes of different comparisons based on the overall survival of ovarian cancer patients, determination of TP53 status, and amount of p53 protein in tumor tissues. Methods: We analyzed and compared a collective of 436 ovarian patient’s data. Extracted data include TP53 mutation status, p53 protein level, and information on the overall survival. Values for p53 protein level in dependence of TP53 mutation status were compared using the Independent-Samples t-Test. Survival analyses were displayed by Kaplan-Meier plots, using the log-rank test to check for statistical significance. Results: We have not found any statistically significant correlations between determination of TP53 status, amount of p53 protein in tumor tissues, and overall survival of ovarian cancer patients. Conclusion: In ovarian tumors both determination of TP53 status as well as p53 protein amount has only limited diagnostic importance.

Determination of Cathepsin B Expression May Offer Additional Prognostic Information for Ovarian Cancer Patients

2002 ◽  
Vol 383 (7-8) ◽  
Author(s):  
A. Scorilas ◽  
S. Fotiou ◽  
E. Tsiambas ◽  
J. Yotis ◽  
F. Kotsiandri ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Cathepsin B ◽  
Prognostic Information

Immunocytochemical Determination of EGFR, OV 632 and OC 125 in Primary Ovarian Cancer Patients

Oncology ◽  
1995 ◽  
Vol 52 (2) ◽  
pp. 145-149 ◽  
Author(s):  
P. Athanassiadou ◽  
P. Athanassiades ◽  
K. Kyrkou ◽  
D. Lazaris ◽  
G. Kyragiannis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Primary Ovarian Cancer

Serum calretinin as a predictor for recurrence and overall survival in ovarian cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17033-e17033
Author(s):  
Pauline Wimberger ◽  
Simon Passek ◽  
Theresa Link ◽  
Yana Vassileva ◽  
Michael Kramer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Calcium Binding ◽  
Tumor Resection ◽  
High Volume ◽  
Primary Diagnosis ◽  
Platinum Resistance ◽  
Serum Samples ◽  
Platinum Based Chemotherapy

e17033 Background: Calretinin (CRT) is a calcium-binding protein, controlling intracellular calcium signaling. Besides its prominent expression in neurons, CRT has diagnostic implications in cancer, particularly in mesothelioma. In a recent liquid biopsy approach, plasma CRT level has been suggested for pre-diagnostic detection of mesothelioma. CRT is also expressed in serous ovarian cancer in about 23% of cases; however, clinical relevance of serum CRT is completely unknown and shall therefore be analyzed, herein. Methods: Serum calretinin (sCRT) was determined by calretinin enzyme-linked immunoabsorbent assay (DLD-Diagnostika GmbH, Hamburg) in a total of 380 serum samples from 134 ovarian cancer patients (thereof n = 115 (86%) with FIGO III or IV), including samples at primary diagnosis and at 4 follow-up reading points in the course of adjuvant treatment. Results: sCRT levels were significantly increased in ovarian cancer patients compared to healthy controls (ED = 0.3ng/ml, p < 0.001) and enabled an accurate discrimination between ovarian cancer and controls (AUC = 0.85). High sCRT levels at primary diagnosis predicted suboptimal debulking surgery without achieving macroscopically complete tumor resection (p < 0.001) and were associated with advanced FIGO-stage (p < 0.001) and high volume of ascites (p < 0.001). Increased sCRT levels at primary diagnosis were an independent predictor of poor PFS (HR:1.99, p = 0.018) and also indicated poor OS (HR:2.49, p = 0.008). Increased sCRT levels before and after platinum-based chemotherapy were independent predictors of poor OS (HR:15.4, p = 0.01; HR:5.59, p = 0.026). Moreover, elevated sCRT levels at primary diagnosis indicated platinum-resistance (p = 0.002). Conclusions: This is the first study, suggesting sCRT as an innovative liquid biopsy marker for ovarian cancer by showing its independent prognostic relevance and its association with primary platinum-resistance.

Determination of response to taxol/carboplatin in ovarian cancer patients

2005 ◽  
Vol 77 (2) ◽  
pp. P61-P61
Author(s):  
T FRUDAKIS ◽  
M THOMAS ◽  
Z GASKIN ◽  
H GOMEZ
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients

scholarly journals Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer

2021 ◽  
Vol 147 (5) ◽  
pp. 1421-1430
Author(s):  
L. C. Hanker ◽  
A. El-Balat ◽  
Z. Drosos ◽  
S. Kommoss ◽  
T. Karn ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Tumor Resection ◽  
Sphingosine Kinase ◽  
Sphingolipid Metabolism ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Sphingosine Kinase 1 ◽  
Cancer Pathogenesis

Abstract Purpose Sphingosine-kinase-1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in ovarian cancer pathogenesis, progression and mechanisms of drug resistance. It is overexpressed in a variety of cancer subtypes. We investigated SPHK1 expression as a prognostic factor in epithelial ovarian cancer patients. Methods Expression analysis of SPHK1 was performed on formalin-fixed paraffin-embedded tissue from 1005 ovarian cancer patients with different histological subtypes using immunohistochemistry. Staining intensity of positive tumor cells was assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. Results In our ovarian cancer collective, high levels of SPHK1 expression correlated significantly with complete surgical tumor resection (p = 0.002) and lower FIGO stage (p = 0.04). Progression-free and overall survival were further significantly longer in patients with high-grade serous ovarian cancer and overexpression of SPHK1 (p = 0.002 and p = 0.006, respectively). Conclusion Our data identify high levels of SPHK1 expression as a potential favorable prognostic marker in ovarian cancer patients.

Sign in / Sign up

Export Citation Format

Share Document